- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Anika Therapeutics Inc
Add to PortfolioANIK:US
13.6300 USD 0.0200 0.15%As of 20:10:00 ET on 05/25/2012.
Snapshot for Anika Therapeutics Inc (ANIK)
| Open: | 13.6600 | Day's Range: | 13.3410 - 13.7200 | Volume: | 36,063 | Bid: | 13.6000 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 13.6100 | 52wk Range: | 5.2400 - 17.7000 | 1-Yr Rtn: | +89.31% | Ask: | 13.6400 |
Key Statistics for ANIK
| Current P/E Ratio (ttm) | 18.4189 |
|---|---|
| Estimated P/E (12/2012) | 17.7013 |
| Earnings Per Share (USD) (ttm) | 0.7400 |
| Est. EPS (USD) (12/2012) | 0.7700 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 187.60 |
| Shares Outstanding (M) | 13.76 |
| Enterprise Value (M USD) (ttm) | 164.40 |
| Enterprise Value/EBITDA (ttm) | 8.00 |
| Price/Book (mrq) | 1.9091 |
| Price/Sale (ttm) | 2.6187 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/03/2012 |
More ANIK Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for ANIK
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for ANIK
Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products and devices. The Company's products, based on hyaluronic acid, promote the repair, protection, and healing of bone, cartilage, and soft tissue. Anika's products include ORTHOVISC and HYVISC which treat osteoarthritis.
| Charles H SherwoodPresident/CEO | Kevin W QuinlanCFO/Treasurer/Secretary |
| Frank J LuppinoChief Operating Officer | Jing-Wen KuoChief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page